Clinical Genomics Technologies

About:

Clinical Genomics develops innovative products for colorectal cancer diagnosis.

Website: http://www.clinicalgenomics.com

Top Investors: OneVentures, MA Growth Ventures, Fraser

Description:

Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrence monitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI.

Total Funding Amount:

$19.7M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Sydney, New South Wales, Australia

Founded Date:

2006-01-01

Contact Email:

contact(AT)clinicalgenomics.com

Founders:

Lawrence LaPointe, Richard J. Sands

Number of Employees:

101-250

Last Funding Date:

2018-06-01

IPO Status:

Private

Industries: